Loading...
•
Sep 30, 2021
Palatin Technologies Q1 2022 Earnings Report
Announced first quarter fiscal year 2022 results and provided a corporate update.
Key Takeaways
Palatin Technologies reported its Q1 2022 financial results, with net revenue increasing by 98% and net revenue per prescription up by 45% compared to the previous quarter. The company is advancing its melanocortin agonist programs, including a Phase 3 pivotal study of PL9643 for dry eye disease and a Phase 2 clinical trial of PL8177 for ulcerative colitis.
Vyleesi net revenue increased 98% over the prior quarter.
Net revenue per Vyleesi prescription increased 45% over the prior quarter.
PL9643 Phase 3 pivotal study in dry eye disease is expected to start next month.
PL8177 Phase 2 clinical trial for ulcerative colitis is scheduled to start in the first half of calendar year 2022.
Palatin Technologies
Palatin Technologies
Forward Guidance
Palatin believes that existing cash and cash equivalents will be sufficient to fund currently anticipated operating expenses through calendar year 2022.